Results 121 to 130 of about 18,827 (200)

Differential synergistic effects of palbociclib and doxorubicin on doxorubicin-resistant cancer cells with diverse tumor origins

Palbociclib is a dual inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Palbociclib has frequently been studied in breast cancer cells and has also been linked to function of P-glycoprotein (P-gp), main protein responsible for cancer drug ...
Yalcin, Gizem Damla, Kazan, Hasan Huseyin, Gündüz, Ufuk, MUTLU, PELİN   +3 more
core   +1 more source

Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity

Cancer Management and Research, 2018
Daniel J Asby,1 Clare L Killick-Cole,1 Lisa J Boulter,1 William GB Singleton,1,2 Claire A Asby,3 Marcella J Wyatt,1 Neil U Barua,1,2 Alison S Bienemann,1 Steven S Gill1,2 1Functional Neurosurgery Research Group, Translational Health Sciences, Bristol ...
Asby DJ, Killick-Cole CL, Boulter LJ, Singleton WGB, Asby CA, Wyatt MJ, Barua NU, Bienemann AS, Gill SS   +8 more
doaj  

CDK8/19 inhibition prevents adaptive resistance to CDK4/6 inhibitors in vitro and in vivo. [PDF]

Cell Rep Med
Mack ZT, Yastrebova M, Lim CU, Ding X, Li J, Khamidullina A, Sharko AC, Saint-Antoine M, Hilimire TA, Schools GP, Digsby K, Eckstrom A, Belcher E, Madiot G, Ji H, Sikirzhitski V, Cai C, Cai G, Singh A, Tatarskiy V, Chen M, Roninson IB, Broude EV.   +22 more
europepmc   +1 more source

Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA. [PDF]

Breast
Liu S, Wang K, Chen H, Wan Z, Dou L, Li S.   +5 more
europepmc   +1 more source

LC-MS/MS-based clinical value exploration of the methionine cycle in luminal breast cancer. [PDF]

Oncol Lett
Wu W, Tu Y, Yao H, Mao Y, Mao C, Xu F, Wang Z.   +6 more
europepmc   +1 more source

Response to: "Proton-pump inhibitor use in combination with a CDK4/6 inhibitor: is formulation the issue?" [PDF]

Oncologist
Chen BF, Huang CC.
europepmc   +1 more source

A COMBINATION OF PALBOCICLIB AND RADIOTHERAPY IMPROVES SURVIVAL IN GLIOBLASTOMA

, 2016
A COMBINATION OF PALBOCICLIB AND RADIOTHERAPY IMPROVES SURVIVAL IN ...
Swapna Joshi (1814116), Mustafa Khasraw (13078896), Kerrie McDonald (6794915)   +2 more
core  

Molecular signatures of triple-negative breast cancer cells acquiring palbociclib resistance via continuous exposure. [PDF]

Oncol Lett
Enomoto D, Iwasa Y, Irie N, Ohata H, Uemichi Y, Mabuchi M, Shimizu T, Takara K.   +7 more
europepmc   +1 more source

Metformin Sensitizes HR+/HER2- Breast Cancer Cells to CDK4/6 Inhibitor via Suppressing of PI3K/AKT/mTOR Signaling Pathway. [PDF]

Drug Des Devel Ther
Zhu L, Yang J, Li F, Wang D, Zhang W, Zhang J, Duan Z, Hu Y, Zhou Y.   +8 more
europepmc   +1 more source

First-Line Palbociclib/Letrozole Versus Ribociclib/Letrozole in Postmenopausal HR-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Real-World Study and an Exploratory Composite Clinical-Inflammatory Risk Score. [PDF]

Medicina (Kaunas)
Tohumcuoğlu M, Yetişir AE, Cinkara ZU, Türker M, Düşgün A, Mirili C, Tazeoğlu D, Köşeci T, Oğul A, Büyükşimşek M.   +9 more
europepmc   +1 more source